Previous 10 | Next 10 |
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Adaptive Biotechnologies Corporation (ADPT) is expected to report $-0.32 for Q3 2023
2023-09-27 17:05:00 ET Summary After a number of updates, there is no change in my investment rating for Adaptive Biotechnologies Corporation. Q2 FY'23 results showed mixed performance, with expectations for FY'23 sales to hit $215mm at the upper end of guidance. Technical ind...
2023-09-26 08:21:55 ET Gainers: Soleno Therapeutics ( SLNO ) +154% . announces positive statistically significant top-line results from randomized withdrawal period of study C602 of DCCR for prader-willi syndrome. Immunovant ( IMVT ) +64% announces positive ini...
SEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ ® ...
2023-09-12 17:27:39 ET Gainers: Rocket Pharmaceuticals ( RCKT ) +30% . Alset Capital Acquisition ( ACAX ) +14% . Veeco Instruments ( VECO ) +7% . InnovAge Holding ( INNV ) +4% . Fulcrum Therapeutics ( FULC ) +4% ...
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat diseas...
2023-08-02 22:38:05 ET Adaptive Biotechnologies Corporation (ADPT) Q2 2023 Results Conference Call August 02, 2023 04:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercia...
2023-08-02 16:45:25 ET Adaptive Biotechnologies press release ( NASDAQ: ADPT ): Q2 GAAP EPS of -$0.33 beats by $0.01 . Revenue of $48.9M (+11.9% Y/Y) beats by $4.01M . Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase fr...
News, Short Squeeze, Breakout and More Instantly...
Adaptive Biotechnologies Corporation Company Name:
ADPT Stock Symbol:
NASDAQ Market:
Adaptive Biotechnologies Corporation Website:
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims...
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequen...
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims...